The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index; 6 of the 18 sources its claims cite were checked for support.
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers
Open accessAbstract
KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRAS G12C, was recently approved for the treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib and other KRAS G12C inhibitors is limited by intrinsic resistance in colorectal cancer (CRC) and by the rapid emergence of acquired resistance in all treated tumors. Therefore, there is an urgent need to develop novel combination therapies to overcome sotorasib resistance and to maximize its efficacy. We assessed the effect of sotorasib alone or in combination with DT2216 (a clinical-stage BCL-X L proteolysis targeting chimera [PROTAC]) on KRAS G12C-mutated NSCLC, CRC and pancreatic cancer (PC) cell lines using MTS cell viability, colony formation and Annexin-V/PI apoptosis assays. Furthermore, the therapeutic efficacy of sotorasib alone and in combination with DT2216 was evaluated in vivo using different tumor xenograft models. We observed heterogeneous responses to sotorasib alone, whereas its combination with DT2216 strongly inhibited viability of KRAS G12C tumor cell lines that partially responded to sotorasib treatment. Mechanistically, sotorasib treatment led to stabilization of BIM and co-treatment with DT2216 inhibited sotorasib-induced BCL-X L/BIM interaction leading to enhanced apoptosis in KRAS G12C tumor cell lines. Furthermore, DT2216 co-treatment significantly improved the antitumor efficacy of sotorasib in vivo. Collectively, our findings suggest that due to cytostatic activity, the efficacy of sotorasib is limited, and therefore, its combination with a pro-apoptotic agent, i.e., DT2216, shows synergistic responses and can potentially overcome resistance.
Overview
CoChat Summary
TL;DR
DT2216, a clinical-stage BCL-XL PROTAC degrader, synergizes with sotorasib in KRASG12C-mutated NSCLC, colorectal cancer, and pancreatic cancer cell lines and xenografts by disrupting sotorasib-induced BCL-XL/BIM interaction and enhancing apoptosis. The combination improved antitumor efficacy over sotorasib monotherapy in preclinical models, supporting clinical testing particularly in KRASG12C-mutated CRC.
Key findings
- DT2216 at 1 µM completely depleted BCL-XL in KRASG12C-mutated cancer cell lines; sotorasib alone showed heterogeneous and only partial viability reduction in sensitive lines, while sotorasib + DT2216 synergistically reduced viability, inhibited colony formation, and induced apoptosis in partially sensitive H358 NSCLC, MIA PaCa-2 PC, and SW837 CRC lines.
- Synergy was caspase-mediated: the pan-caspase inhibitor QVD-OPh significantly abrogated the sotorasib + DT2216 effect; inhibition of BCL-XL, but not BCL-2 or MCL-1, sensitized the three partially sensitive cell lines to sotorasib.
- Mechanistically, sotorasib upregulated BIM and BMF, decreased p-BIM (S69), and increased BCL2L11; sotorasib selectively induced BCL-XL/BIM interaction, which was disrupted by DT2216-mediated BCL-XL degradation.
- In xenografts, DT2216 (15 mg/kg q4d i.p.) plus sotorasib (10 mg/kg 5 days/week p.o.) significantly inhibited tumor growth versus sotorasib monotherapy in H358, MIA PaCa-2, and SW837 models (n = 7–8 mice/group), with no significant body-weight change or clinically significant blood-count decrease.
Methods
- In vitro: KRASG12C-mutated H358 NSCLC, MIA PaCa-2 PC, and SW837 CRC cell lines, plus non-KRASG12C-mutated lines; assays included MTS viability, colony formation, Annexin-V/PI apoptosis, immunoblot, and immunoprecipitation.
- In vivo: H358, MIA PaCa-2, and SW837 xenograft models treated with vehicle, DT2216, sotorasib, or combination; tumor volume, BCL-XL densitometry, and IHC for Ki67 and cleaved caspase-3 were assessed.
- Statistics: one-way ANOVA with Tukey’s multiple comparison test and two-sided Student’s t-test; viability data from n = 6 replicate cell cultures, xenograft data from n = 7–8 mice at treatment start, and densitometry from n = 4 mice/group.
Limitations
- The paper states no explicit limitations section.
- Evident from the text: all findings are preclinical, using cell lines and mouse xenografts only, with no clinical validation; safety is limited to mouse body weights and blood cell counts.
- Evident from the text: synergy was observed only in cell lines partially sensitive to sotorasib, while non-KRASG12C-mutated and non-responding KRASG12C lines did not respond to the combination; the study does not directly model acquired sotorasib resistance in vivo.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 BCL-XL degradation with DT2216 enhances the antitumor efficacy of sotorasib in KRASG12C-mutated xenograft models. a–c Tumor volume changes in H358 (a), MIA PaCa-2 (b) and SW837 (c) xenografts after they were treated with vehicle, DT2216 (DT, 15 mg/kg, every four days [q4d], i.p.), sotorasib (Sot, 10 mg/kg, 5 days a week, p.o.) or a combination of the two (Combo). Data are presented as mean ± SEM (n = 7–8 mice at the start of treatment). Statistical significances in a–c were determined by two-sided Student’s t-test at day-41, day-25 and day-25 in H358, MIA PaCa-2 and SW837 xenografts, respectively. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. d–f Changes in tumor volumes of individual mice in H358 (d), MIA PaCa-2 (e) and SW837 (f) xenografts at the end of treatment calculated as: tumor volume at the end of treatment − baseline tumor volume. g–i Densitometric analysis showing BCL-XL protein levels as determined by immunoblotting in H358 (g), MIA PaCa-2 (h) and SW837 (i) xenograft tumors at the end of treatments as in a–c (n = 4 mice per group). The representative immunoblots are shown in Additional file 1: Fig. 12a](/paper-figures/833a6ecd5c6c4d8bbf758540b4ac7dcd/bcl-xl-protac-degrader-dt2216-synergizes-with-sotorasib-in-preclinical-models-of-figure-2.jpg)
Verification
Claims the paper makes
3 Valid · 1 Not valid · 4 Not checked · 29 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Recently, our group has reported platelet-sparing targeting of BCL-XL by proteolysis targeting chimeras (PROTACs) exemplified by DT2216.”
§ BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers > Abstract > Supplementary Information
What the sources say
- Supportedcites [8] Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-X L PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25(12):1938–47. source
The Discussion says the authors developed a BCL-XL-targeting PROTAC and identifies DT2216 as their lead degrader, which significantly reduces platelet toxicity. The Results section reports only mild platelet-count reductions with DT2216, in contrast to severe thrombocytopenia with ABT263. The paper does not claim DT2216 is entirely free of platelet toxicity. (LLM, conf=0.94)
- Supportedcites [9] He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, et al. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020;13(1):95. source
The Introduction says the authors recently reported developing DT2216 as a Bcl-xL degrader that spares platelets. The Discussion identifies DT2216 as a Bcl-xL PROTAC and reports that it targets lymphoma cells without significant platelet toxicity. The supplied passages do not give page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [10] Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, et al. Discovery of PROTAC BCL-X L degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020;192:112186. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Sotorasib or sotorasib + DT2216 had no considerable effect on other BCL-2 proteins (Additional file 1: Fig. 7a-d).”
§ BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers > Abstract > Supplementary Information
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, sotorasib caused only partial reduction in viability in the sensitive cell lines (referred to as partially sensitive cell lines).”
§ BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers > Abstract > Supplementary Information
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that 1 µM of DT2216 can completely deplete BCL-XL in different KRASG12C-mutated cancer cell lines (Additional file 1: Fig. 1a-d)”
§ BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers > Abstract > Supplementary Information
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“as well as enhanced inhibition of colony formation and apoptosis induction compared to sotorasib monotherapy (Fig. 1a–d).”
§ BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers > Abstract > Supplementary Information
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
22 more claims
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 8
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“a recent study showed that the Bcl-xL–targeted PROTAC, DT2216, enhanced the therapeutic efficacy of sotorasib in the SW837 KRASG12CMT model, and demonstrated also a good tolerability”
From Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer (2023) · cites this paper as [50]
Citations
Cites
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · cited 1×
“To the Editor, KRAS mutations are the most common drivers in nonsmall cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic cancer (PC) [1].”
BackgroundProgrammed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Self-citationVertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Luciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., & Auberger, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206792 · Cited by 477
Bcl-2 family proteins are essential for platelet survival
Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427
Schoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347849 · Cited by 351
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
He, Y., Koch, R., Budamagunta, V., Zhang, P., Zhang, X., Khan, S., Thummuri, D., Ortiz, Y. T., Zhang, X., Lv, D., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00928-9 · Cited by 139
Self-citation
Cited by
Advances and challenges in the treatment of lung cancer
Li, Y., Yan, B., & He, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115891 · Cited by 462
Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders
Hanzl, A., Casement, R., Imrichova, H., Hughes, S. J., Barone, E., Testa, A., Bauer, S., Wright, J., Brand, M., Ciulli, A., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01177-2 · Cited by 133
PROTAC therapy as a new targeted therapy for lung cancer
Li, J. W., Zheng, G., Kaye, F. J., & Wu, L. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.011 · Cited by 87
Self-citationTreatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
O’Sullivan, É., Keogh, A., Henderson, B., Finn, S. P., Gray, S. G., & Gately, K. A. (2023) · Cancers · doi:10.3390/cancers15061635 · Cited by 87
“A recent study showed synergy between DT2216 (a clinical-stage BCL-XL PROTAC) and sotorasib in KRAS G12C-mutated NSCLC, CRC, and pancreatic cancer preclinical models [76].”
BackgroundTherapy-induced senescence as a component of tumor biology: Evidence from clinical cancer
Saleh, T., Bloukh, S., Hasan, M., & Shboul, S. A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188994 · Cited by 55
Metadata
- Authors
- Khan, S., Wiegand, J., Zhang, P., Hu, W., Thummuri, D., Budamagunta, V., Hua, N., Jin, L., Allegra, C. J., Kopetz, S. E., Zajac-Kaye, M., Kaye, F. J., Zheng, G., & Zhou, D.
- Affiliations
- University of Florida (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Khan, Sajid
- Zhou, Daohong
- ORCID
- Venue
- Journal of Hematology & Oncology
- Published
- 2022-03-09
- Volume
- 15
- Issue
- 1
- Pages
- 23-23
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC8905794
- OpenAlex
- W4221046553
- Semantic Scholar
- e05c52962856b53b7e8cb6ea6a025d298235d974
- Cited by
- 62
- References
- 13
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 12 · 2023: 15 · 2022: 8
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Cancer Institute (R01 CA242003)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- sotorasib, KRAS G12C, apoptosis, combination therapy, acquired drug resistance, non-small cell lung cancer, colorectal cancer, pancreatic cancer, tumor xenografts, KRAS inhibitors
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), bcl-X Protein, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. https://app.cochat.ai/papers/10.1186/s13045-022-01241-3
- The paper
- Khan, S., Wiegand, J., Zhang, P., Hu, W., Thummuri, D., Budamagunta, V., Hua, N., Jin, L., Allegra, C. J., Kopetz, S. E., Zajac-Kaye, M., Kaye, F. J., Zheng, G., & Zhou, D. (2022). BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-022-01241-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.